Pacira Pharmaceuticals (NSDQ:PCRX) said today that it priced $300 million of convertible 2.375% senior notes due 2022 in a private placement to qualified institutional buyers. The Parsippany, N.J.-based company also gave purchasers a 30-day option to buy an additional $45 million aggregate principal amount of notes. Get the full story at our sister site, Drug Delivery […]
Neuromodulation/Neurostimulation
AcelRx Pharmaceuticals gains on Q4 earnings
Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results. The Redwood City, Calif.-based company pared its losses to -$9.7 million, or -21¢ per share, on sales of $6.4 million for the 3 months ended Dec. 31, for bottom-line growth of 8.2% on sales growth of […]
FDA accepts AcelRx’s NDA for Dsuvia pain reliever
AcelRx Pharmaceuticals (NSDQ:ACRX) said today that the FDA accepted the company’s New Drug Application for its Dsuvia pain relief therapy. The federal watchdog set a target decision date for October 12 this year. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator to patients with moderate-to-severe […]
Study: tDCS paired with cognitive video game training can help MS patients
Combined therapy pairing transcranial direct current stimulation and cognitive training computer games can increase problem solving ability and response time in patients with multiple sclerosis, according to a new study. Results from the study, performed by researchers at NYU’s Langone’s Multiple Sclerosis Comprehensive Care Center, was published today in the journal Neuromodulation: Technology at the […]
Adapt Pharma seeks regulatory nod for naloxone nasal spray in Europe
Adapt Pharma said today that it filed a European Marketing Application for its naloxone hydrochloride nasal spray for the treatment of opioid overdose. The Dublin-based company’s product is a ready-to-use, needle-free device that delivers a single dose of naloxone in an 0.1 mL nasal spray and does not require assembly prior to use, according to […]
Fresenius Kabi launches Dilaudid injection in Simplist prefilled syringes
Fresenius (NYSE:FMS) business group Fresenius Kabi said today that its Dilaudid hydromorphone HCl injection is available in 4 different presentations of the Simplest prefilled syringes. The Lake Zurich-Ill. company’s Simplist syringes have a 2-year shelf life and do not require any assembly or point-of care preparation. Get the full story at our sister site, Drug Delivery Business […]
Helius Medical closes $10m offering for portable neurostim trials
Helius Medical Technologies (TSX:HSM) said today that it closed an offering worth nearly $10 million (C$12.5 million) for the portable neurostimulation device it’s developing. Newtown, Pa.-based Helius said it plans to use the proceeds from the 6.6-million-share flotation to complete a trial of the PoNS therapy in treating mild to moderate brain injury and the launch […]
PathMaker Neurosystems wins BpiFrance grant to support MyoRegulator clinical dev
PathMaker Neurosystems said today that it won a grant from BpiFrance to support the company’s MyoRegulator neuromodulation device designed to treat patients with neuromotor spasticity. The MyoRegulator device, based on PathMaker’s DoubleStim technology, is designed to provide simultaneous, non-invasive stimulation at spinal and peripheral locations, the Boston and Paris-based company said. The grant will support the initiation of […]
AcelRx touts Dsuvia data for burn victims
AcelRx Pharmaceuticals (NSDQ:ACRX) said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or injury. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in […]
Helius Medical touts data from multiple sclerosis pilot study of PONS system
Helius Medical Technologies said today that clinical data from a multiple sclerosis pilot study of its portable neuromodulation stimulator was published in the Multiple Sclerosis Journal: Experimental, Translational and Clinical. The company’s PONS system is designed to treat neurological symptoms, caused by trauma or disease, non-invasively through the tongue. Helius’ pilot study evaluated its PONS device combined […]
FDA accepts Flexion’s NDA for osteoarthritis steroid injection
Flexion Therapeutics (NSDQ:FLXN) said today that the FDA accepted its New Drug Application for Zilretta – its extended-release steroid injection. The Burlington, Mass.-based company won Fast Track status from the watchdog for its osteoarthritis injection in 2015. Flexion touts Zilretta as the 1st intra-articular, extended-release therapy for patients with knee osteoarthritis pain. The injection uses microsophere technology […]